Search International and National Patent Collections
Some content of this application is unavailable at the moment.
If this situation persists, please contact us atFeedback&Contact
1. (FR2740685) COMPOSITION PHARMACEUTIQUE TOPIQUE MOUSSANTE POUR LE TRAITEMENT DES DERMATOSES, INDUITES PAR PITYROSPORUM OVALE

Office : France
Application Number: 9513202 Application Date: 08.11.1995
Publication Number: 2740685 Publication Date: 09.05.1997
Publication Kind : A1
IPC:
A61K 9/12
A61K 31/4418
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9
Medicinal preparations characterised by special physical form
10
Dispersions; Emulsions
12
Aerosols; Foams
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
435
having six-membered rings with one nitrogen as the only ring hetero atom
44
Non-condensed pyridines; Hydrogenated derivatives thereof
4418
having a carbocyclic ring directly attached to the heterocyclic ring, e.g. cyproheptadine
CPC:
A61K 9/122
A61K 31/4418
Applicants: PF MEDICAMENT
Inventors: LEVERD ELIE
LACROUX MARTINE
MROZ COMBESSIS DANIELLE
BOUGARET JOEL
MROZ CHRISTIAN
Priority Data: 9513202 08.11.1995 FR
Title: (FR) COMPOSITION PHARMACEUTIQUE TOPIQUE MOUSSANTE POUR LE TRAITEMENT DES DERMATOSES, INDUITES PAR PITYROSPORUM OVALE
Abstract:
(EN) A topical foamable pharmaceutical composition for treating skin diseases induced by oval Pityrosporum, containing (i) 0.1-10.0 wt %, preferably 2.1-6.0 wt % of ciclopirox or ciclopiroxolamine as the antifungal active principle, and (ii) 0.5-35.0 wt %, preferably 3-20 wt % and especially 5-15 wt % of a surfactant selected from alkylbetaines, alkylamidobetaines, cocamidoalkylamines and derivatives thereof, as well as mixtures thereof.
(FR)

Composition pharmaceutique moussante à usage topique destinée au traitement des dermatoses induites par Pityrosporum ovale, caractérisée en ce qu'elle contient:
(i) à titre de principe actif anti-fongique 0,1 à 10,0% en poids, de préférence 2,1 à 6,0%, de ciclopirox ou de ciclopiroxolamine,
(ii) 0,5% à 35,0% en poids, de préférence de 3 à 20%, et plus particulièrement de 5 à 15%, d'un tensio-actif choisi parmi les alkyl-bétaïnes, les alkyl-amidobétaïnes ainsi que leurs mélanges.


Also published as:
EP0862433DE000069623641PT862433WO/1997/017075